The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2021 | JACKPOT8: DZD4205 in peripheral T-cell lymphoma
Won-Seog Kim, MD, PhD, Sungkyunkwan University, Seoul, South Korea, discusses preliminary safety and efficacy data from the Phase I/II JACKPOT8 trial (NCT04105010) of DZD4205, a selective JAK1 inhibitor, in patients with peripheral T-cell lymphoma (PTCL). Preliminary tests has shown anti-tumor activity and in the Phase I/II trial, 150 mg or 250 mg of DZD4205 was administered. Whilst efficacy was the same in both doses, the lower dose had fewer adverse effects. Prof. Kim additionally reports a durable response and several grade 3 toxicities in patients receiving DZD4205. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
